Observational studyFuture oncology (London, England)2026
Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communication.
Observational study in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04584853 (PreOperative Endocrine Therapy for Individualised Care With Abemaciclib), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study explored perceptions and initial experiences of abemaciclib, a CDK4/6 inhibitor, plus endocrine therapy (ET) as adjuvant targeted therapy for early breast cancer with high risk of recurrence (EBC). Early onset diarrhea is the most common side-effect, but its impact is often under-recognized and may affect treatment adherence.
methodsThree serial interviews were conducted with five women with EBC recruited from four UK breast units. The baseline interview took place before the start of treatment, follow-up interviews 4 and 8 weeks later. Transcripts were analyzed following the framework approach to thematic analysis.
resultsDiarrhea at follow-up was reported by 4 women, and in 3 this was the most bothersome symptom. It was usually managed by anti-diarrheal drugs and/or dietary modifications. One woman discontinued treatment due to its effect on day-to-day living. All patients said they adhered to treatment. Beliefs that the drug offered a lower risk of recurrence helped some to tolerate side-effects, alongside support from their clinical teams.
conclusionThese initial findings showed that abemaciclib plus ET was generally manageable. Regular follow-up in this patient cohort could support early detection of symptoms. Further longitudinal real-world research into patients' experiences with abemaciclib plus ET for EBC is warranted.
trial registrationNCT04584853 (06/07/2020).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.